Education
About Us
Working with TipRanks
Follow Us
Ibio Inc (IBIO)
NASDAQ:IBIO
IBIO Stock Chart & Stats
$2.41
-$0.02(-0.74%)
At close: 4:00 PM EST
$2.41
-$0.02(-0.74%)
Day’s Range― - ―
52-Week Range$0.56 - $6.89
Previous CloseN/A
Volume55.53K
Average Volume (3M)2.32M
Market Cap
$73.87M
Enterprise Value$10.31M
Total Cash (Recent Filing)$28.67M
Total Debt (Recent Filing)$2.45M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 18, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding32,540,943
10 Day Avg. Volume1,074,870
30 Day Avg. Volume2,319,101
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.54
Price to Sales (P/S)20.03
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.14
Enterprise Value/Revenue34.36
Enterprise Value/Gross Profit937.20
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
$5.50Price Target Upside128.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Discovery Platform And PipelineProprietary AI discovery engine has produced multiple antibody candidates moving toward clinical testing, supporting pipeline diversification and potential value creation.
Commercial And Formulation PotentialPotential to co-formulate with GLP‑1 therapies and leverage fully scalable antibody manufacturing could expand commercial opportunities and attractiveness to partners.
First-in-class Antibody DifferentiationLead antibody targeting activin E represents the only known antibody-based approach to this target, offering scarcity value and a distinct therapeutic strategy versus RNA-based competitors.
Bears Say
Cash Runway ShortfallLimited cash resources relative to spending indicate a need for additional financing before later-stage clinical programs can advance.
Clinical Efficacy UncertaintyAbsence of disclosed weight-loss outcomes creates uncertainty about whether activin E suppression will translate into meaningful obesity benefits in humans.
Financing And Dilution RiskSubstantial fully diluted share count combined with upcoming funding needs raises the risk of investor dilution if equity financing is required.
Ibio News
IBIO FAQ
What was Ibio Inc’s price range in the past 12 months?
Ibio Inc lowest stock price was $0.56 and its highest was $6.89 in the past 12 months.
What is Ibio Inc’s market cap?
Ibio Inc’s market cap is $73.87M.
When is Ibio Inc’s upcoming earnings report date?
Ibio Inc’s upcoming earnings report date is May 18, 2026 which is in 95 days.
How were Ibio Inc’s earnings last quarter?
Ibio Inc released its earnings results on Feb 10, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.05.
Is Ibio Inc overvalued?
According to Wall Street analysts Ibio Inc’s price is currently Undervalued.
Does Ibio Inc pay dividends?
Ibio Inc does not currently pay dividends.
What is Ibio Inc’s EPS estimate?
Ibio Inc’s EPS estimate is -0.06.
How many shares outstanding does Ibio Inc have?
Ibio Inc has 32,540,943 shares outstanding.
What happened to Ibio Inc’s price movement after its last earnings report?
Ibio Inc reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -8%.
Which hedge fund is a major shareholder of Ibio Inc?
Currently, no hedge funds are holding shares in IBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ibio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (128.22% Upside)
$5.50 (128.22% Upside)
Blogger Sentiment
Bullish
IBIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-35.21%
12-Months-Change
Fundamentals
Return on Equity
-54.50%
Trailing 12-Months
Asset Growth
161.68%
Trailing 12-Months
Company Description
Ibio Inc
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
IBIO Stock 12 Month Forecast
Average Price Target
$5.50
▲(128.22% Upside)
Technical Analysis
Minerva Neurosciences
―
Pulmatrix
―
Chemomab Therapeutics
―
Aspire Biopharma Holdings
―
FibroBiologics, Inc.
―
Ownership Overview
1.13%
Insiders
1.26% Mutual Funds
9.62% Other Institutional Investors
85.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---